RYZUMVI Expected to be Commercially Available in the U.S. in the First Half of 2024 PITTSBURGH, and FARMINGTON HILLS, Mich., Sept. 27, 2023 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS), a global...

Viatris Inc. (NASDAQ: VTRS), a global healthcare company, today announced that it has been named to TIME's World's Best Companies 2023 list. This recognition of companies changing the world is...

Tentative approval will help enhance access to WHO-recommended paediatric regimen with the goal of improved adherence of HIV treatment for children in low- and middle-income countries PITTSBURGH...

Reports Total Revenues of $3.92 Billion; U.S. GAAP Net Earnings of $264 Million; Adjusted EBITDA of $1.31 Billion; U.S. GAAP Net Cash Provided by Operating Activities of $515 Million; and Free...

FDA assigns PDUFA target action date of March 8, 2024 New Drug Application supported by positive Phase III efficacy and safety clinical trial results Milestone builds upon Viatris' long-standing...

Launch demonstrates companies' commitment to bringing complex generic medicines to the market to help increase patient access PITTSBURGH and WOODBURY, Minn., July 31, 2023 /PRNewswire/ -- Viatris...

Viatris Inc. (NASDAQ: VTRS) plans to report its second quarter 2023 financial results on Monday, August 7 before the open of the U.S. financial markets. Chief Executive Officer Scott A. Smith,...

Viatris has received notice that an applicant submitted an abbreviated new drug application (“ANDA”) seeking FDA approval for a generic to Tyrvaya® (varenicline solution) Nasal Spray, with...